Exendin‐4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease

Abstract

AbstractNeurodegenerative disorders, which affect millions worldwide, are marked by a steady decline of neurons that are selectively susceptible. Due to the complex pathological processes underlying neurodegeneration, at present, there is no viable therapy available for neurodegenerative disorders. Consequently, the establishment of a novel therapeutic approach for such conditions is a clinical void that remains. The potential significance of various peptides as neuroprotective interventions for neurodegenerative disorders is gaining increasing attention. In the past few years, there has been growing scientific interest in glucagon‐like peptide‐1 receptor agonists due to their claimed neuroprotective effects. Exendin‐4 is a glucagon‐like peptide‐1 receptor agonist that is known to possess anti‐diabetic effects and does not degrade for hours, making it a superior candidate for such disorders. Moreover, exendin‐4's neuroprotective effects have been reported in several preclinical studies. Exendin‐4's diverse therapeutic targets suggest its potential therapeutic uses in neurodegenerative ailments like Alzheimer's disease and Parkinson's disease and have garnered an increasing amount of attention. Given the substantial body of evidence supporting the neuroprotective potential of exendin‐4 in various research models, this article is dedicated to exploring the promising role of exendin‐4 as a therapeutic agent for the treatment and management of Alzheimer's disease and Parkinson's disease. This review draws insights from the findings of numerous preclinical and clinical studies to highlight the collective neuroprotective advantages of exendin‐4 and the potential mechanisms that underlie its neuroprotective effects.